Blog

The LDL phenotype and size result has been removed from our most recent LPP™ report due to misinterpretation and lack of therapeutic guidance. LDL phenotype is an outdated designation to identify a large LDL type from a small LDL type. LDL phenotype was used in the past because accurate data on individual LDL subgroups was not available or inaccurate. Today the LPP™ test gives accurate information on large-buoyant and small-dense LDL subgroups and this is much more specific for treatment... Read More

SpectraCell Laboratories has officially been granted a license to provide its Lipoprotein Particle Profile™ (LPP™) test, which assesses cardiovascular risk, to New York state physicians and patients. The recently patented LPP™ test has been commercially available to the other 49 states since 2006. SpectraCell began the process of acquiring a licensure in 2008 with an application submission the state of New York. The laboratory underwent an initial inspection by the New York State... Read More

The answer is simple: cell membrane flexibility.  Every cell has a cell membrane.  When this cell membrane is rigid, it does not work well.  When it is flexible, the chemicals that run our bodies - hormones, proteins, enzymes, vitamins, minerals, fats, etc - can move in and out of cells efficiently as needed, thus making the cells healthier, since the materials they need to function well are available.  When the cells work well, the tissues that are made of cells work... Read More

Houston, TX- January 28, 2011. SpectraCell Laboratories has recently been awarded a patent on their Lipoprotein Particle Profile™ (LPP™) test which is used to measure cardiovascular risk. The LPP™ has been commercially available since 2006, and is a type of advanced cholesterol test that measures lipoprotein subgroups. The LPP™ gives more accurate estimation of cardiovascular risk compared to a routine cholesterol test. The patent was awarded for use of a “Method for Analyzing Blood for... Read More